Abstracts tagged "anti-CCP antibodies"

Abstract Number: 2608 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi^1,2, Shinsuke Yasuda¹, Ryo Hisada¹, Kazumasa Ohmura¹, Sanae Shimamura¹, Yuka Shimizu¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Miho Suzuki³, Yoshihiro Matsumoto⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Product research department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ⁴Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Consecutive RA patients who initiated treatment with TCZ between December 2013 and September 2015 were enrolled in our prospective study. All patients met 2010…
Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Dmitry Karayev¹, Guoqiu Shen¹, Yvonne Lam¹, Andrew Rimmer¹, Nayan Lal¹, Eugene Karayev¹, Kristine Azarraga¹, Ronald A. Blum¹, Allan L. Metzger¹, Robert I. Morris¹ and Arash A. Horizon², ¹Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, ²Center for Rheumatology Medical Group, Los Angeles, CA
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…
Abstract Number: 3017 • 2016 ACR/ARHP Annual Meeting
Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
M. Kristen Demoruelle¹, Monica Purmalek², Heather Rothfuss³, Michael Weisman⁴, Lindsay Kelmenson¹, Michael Mahler⁵, Jill M. Norris⁶, Brian Cherrington³, Mariana Kaplan², V. Michael Holers¹ and Kevin D. Deane¹, ¹Rheumatology Division, University of Colorado Denver, Aurora, CO, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Zoology and Physiology, University of Wyoming, Laramie, WY, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Research and Development, Inova Diagnostics, San Diego, CA, ⁶Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: The initial site of anti-citrullinated protein antibody (ACPA) generation in RA has been proposed to be a mucosal site. We have previously demonstrated ACPA…
Abstract Number: 503 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Titer and Prevalence Is Influenced By Age at Rheumatoid Arthritis Onset- Analysis Based on a Nationwide Database in Japan
Eri Kato¹, Tetsuji Sawada¹, Koichiro Tahara², Haeru Hayashi², Mayu Tago², Hiroaki Mori², Shigeru Yoshizawa³, Jinju Nishino⁴, Toshihiro Matsui⁵ and Shigeto Tohma⁶, ¹Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ²Rheumatology, Tokyo Medical University, Tokyo, Japan, ³Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, ⁴Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ⁵Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Previous studies demonstrated the lower prevalence of anti-CCP antibody and rheumatoid factor (RF) in elderly-onset rheumatoid arthritis (EORA). However, anti-CCP antibody titer in EORA…
Abstract Number: 507 • 2016 ACR/ARHP Annual Meeting
Comparison of Body Mass Index, Anti-Citrullinated Peptides Antibodies Status and Periodontal Condition in First Degree Relatives Individuals to Rheumatoid Arthritis
Sonia Unriza-Puin¹, Wilson Bautista-Molano^2,3, Gloria Lafaurie⁴, Rafael R. Valle-Oñate⁵, Phillipe Chalem⁶, Lorena Chila³, Juan Manuel Bello⁷ and Consuelo Romero Sanchez^3,8, ¹Unit of Oral Basic Investigation, School of Dentistry, Universidad El Bosque, Bogota, Colombia, ²Rheumatology Department School of Medicine HMC / UMNG, Bogotá, Colombia, ³Unit of Oral Basic Investigation, School of Dentistry, Universidad El Bosque, Bogotá, Colombia, ⁴Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogotá, Colombia, ⁵Rheumatology, Rheumatology Department School of Medicine HMC / UMNG, Bogota, Colombia, ⁶Fundación Instituto de Reumatología Fernando Chalem, Bogotá, Colombia, ⁷Rheumatology Department School of Medicine HMC / UMNG, Bogota, Colombia, ⁸Rheumatology, School of Medicine HMC / UMNG, Bogota, Colombia
Background/Purpose: Association studies in rheumatoid arthritis (RA) have been focused in the pre-clinical phases of the disease in asymptomatic individuals with higher risk to develop…
Abstract Number: 509 • 2016 ACR/ARHP Annual Meeting
Association of Anti-Citrullinated Protein Antibody Positivity and Titer Levels to Low Hand BMD, and the Consequence of Low Hand BMD on DAS28 (CRP) Remission in Established RA: Findings from a US Observational Cohort
H Ahmad¹, E Alemao¹, Z Guo¹, M Frits², Michael Weinblatt² and N A Shadick², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hand bone mineral density (BMD) loss is an independent predictor of radiographic joint progression,1 and a potential indicator of vertebral and non-vertebral fracture risk.2…
Abstract Number: 536 • 2016 ACR/ARHP Annual Meeting
Precision Medicine in Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis on the Diagnostic Accuracy of Anti-CCP Tests for the Diagnosis of Rheumatoid Arthritis
Gaia Gallo¹, Barbara Mascialino¹, Donna Fountain², Kevin Cadwell² and Sigrid Sjolander¹, ¹Immuno Diagnostics, Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden, ²PHMR, Berkeley Works, Berkley Grove, London, London, United Kingdom
Background/Purpose: Biological markers are objective molecular indicators possessing diagnostic, prognostic and predictive utility. The detection of antibodies to cyclic citrullinated peptides (Anti-CCP) may occur long…
Abstract Number: 576 • 2016 ACR/ARHP Annual Meeting
Anti-CCP3.1 and Anti-CCP3-IgA Are Elevated in RA-Free Subjects with Idiopathic Pulmonary Fibrosis
Scott Matson¹, Joshua J. Solomon², Jeffrey J. Swigris², Jonathan Chung³, Michael Mahler⁴, Kevin D. Deane⁵ and M. Kristen Demoruelle⁵, ¹Medicine, University of Colorado Denver, Aurora, CO, ²Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, ³Radiology, University of Chicago Medical Center, Chicago, IL, ⁴Research and Development, Inova Diagnostics, San Diego, CA, ⁵Rheumatology Division, University of Colorado Denver, Aurora, CO
Background/Purpose: In RA-associated interstitial lung disease (RA-ILD), higher levels of anti-CCP antibodies have been associated with the presence and severity of ILD suggesting a potential…
Abstract Number: 588 • 2016 ACR/ARHP Annual Meeting
Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards
Kazuko Shiozawa¹, Ken Tsumiyama² and Shunichi Shiozawa², ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: A newly discovered anti-carbamylated protein antibody (anti-CarP) is found prior to disease-onset, associates with the conversion towards arthralgia and with a more severe disease…
Abstract Number: 644 • 2016 ACR/ARHP Annual Meeting
Seroprevalence and Its Impact on Radiographic Damage in Korean Rheumatoid Arthritis Patients Starting Biologics
Kichul Shin¹, Seongjun Ha², Inkyung Jung³, Hyoun-Ah Kim⁴ and Shin-Seok Lee⁵, ¹Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of, ³Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ⁴Ajou University Hospital, Suwon, South Korea, ⁵Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of
Background/Purpose: High titers of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACCP) are poor prognostic factors for rheumatoid arthritis (RA) patients. Only few studies…
Abstract Number: 1037 • 2016 ACR/ARHP Annual Meeting
Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort
Monika Hansson¹, Linda Mathsson-Alm², Anthony Marotta³ and Sascha Swiniarski⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Thermo Fisher Scientific, Uppsala, Sweden, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴ImmunoDiagnostics Division Thermo Fisher Scientific, Phadia GmbH, Freiburg, Germany
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) coupled with an effective treatment strategy is a key imperative in the effective management of disease. Anti-citrullinated peptide…
Abstract Number: 110 • 2015 ACR/ARHP Annual Meeting
Genome-Wide DNA Epigenetic Profiling of Monozygotic Twins[L1] Discordant for ACPA or ACPA-Positive Rheumatoid Arthritis Reveals Novel Associated Genes
David Gomez¹, Malin Almgren², Louise Sjoholm², Aase Haj Hensvold³, Andrew Feinberg⁴, L. Klareskog⁵, Tomas Ekstrom^2,6 and Anca I Catrina⁵, ¹Unit of Computational Medicine Karolinska Institutet Center for Molecular Medicine Karolinska University Hospital, stockholm, Sweden, ²Laboratory for Medical Epigenetics, Dept. of Clinical Neuroscience, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁴Department of Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Departmen of Clinical Neuroscience, karolinska Institute, Stockholm, Sweden
Background/Purpose: Occurrence and progression of complex autoimmune diseases are orchestrated by interactions between genes and environment, in part mediated by epigenetic mechanisms. It is yet…
Abstract Number: 2088 • 2015 ACR/ARHP Annual Meeting
Immature Dendritic Are Potent OC Precursors in RA and Are Targeted By RA-Specific Antibodies
Akilan Krishnamurthy¹, Vijay Joshua², Heidi Wähämaa³, Vivianne Malmström³, Khaled Amara¹, Jimmy Ytterberg⁴ and Anca I Catrina³, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Immature dendritic cells (iDC) have been shown to act as OC precursors and are important cell players in the pathogenesis of RA. We aimed…
Abstract Number: 152 • 2015 ACR/ARHP Annual Meeting
Anti-CCP Positive Patients without Clinical Synovitis Progress If Ultrasound Positive
Jackie L. Nam¹, Elizabeth M.A. Hensor¹, Laura Hunt¹, Philip G. Conaghan², Richard J. Wakefield¹ and Paul Emery³, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: To determine whether ultrasound can identify which anti-cyclic citrullinated peptide (anti-CCP) antibody positive patients with musculoskeletal (MSK) symptoms and without clinical synovitis progress to…
Abstract Number: 2212 • 2015 ACR/ARHP Annual Meeting
Identification of a Novel Chemokine-Dependent Molecular Mechanism Underlying Rheumatoid Arthritis-Associated Autoantibody-Mediated Bone Destruction
Akilan Krishnamurthy¹, Vijay Joshua², Aase Haj Hensvold³, Tao Jin⁴, Meng Sun³, Marianne Engström³, Khaled Amara¹, Malin MAgnusson⁴, Camilla Svensson⁵, Vivianne Malmström³, L. Klareskog¹, Heidi Wähämaa³ and Anca I Catrina³, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, Gothenberg, Sweden, ⁵Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA)-specific anti-citrullinated protein/peptide antibodies (ACPAs) appear before disease onset and are associated with bone destruction. We aimed to dissect the role of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.